Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.51 |
| ▸ | ADA | P00813 | 1/20 | 0.45 |
| ▸ | ADK | P55263 | 7/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3292590 | 1.00 | ADORA2A (0.51) | ADORA2AADAADKADORA3ADORA1 | |
| SCHEMBL13068434 | 0.90 | ADORA2A (0.50) | ADORA2AADAADKADORA3ADORA1 | |
| SCHEMBL13005687 | 0.89 | ADORA2A (0.52) | ADORA2AADAADKADORA3ADORA1 | |
| SCHEMBL13725495 | 0.88 | ADORA2A (0.48) | ADORA2AADAADKADORA3ADORA1 | |
| SCHEMBL5006780 | 0.87 | ADORA2A (0.51) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL13021352 | 0.85 | ADORA2A (0.65) | ADORA2AADKADORA3ADORA1ADORA2B | |
| SCHEMBL15241432 | 0.85 | ADORA2A (0.65) | ADORA2AADKADORA3ADORA1ADORA2B | |
| SCHEMBL2786078 | 0.85 | ADORA2A (0.65) | ADORA2AADKADORA3ADORA1ADORA2B | |
| SCHEMBL13091999 | 0.85 | ADORA2A (0.65) | ADORA2AADKADORA3ADORA1ADORA2B | |
| SCHEMBL13650003 | 0.85 | ADORA2A (0.65) | ADORA2AADKADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-12-09 | — | — | US | disclosed |
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-12-09 | — | — | US | disclosed |
| EP-1660511-B1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2010-11-03 | — | — | EP | disclosed |
| US-7713941-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-05-11 | — | — | US | disclosed |
| US-7713941-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-05-11 | — | — | US | disclosed |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2008-08-21 | — | — | US | disclosed |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2008-08-21 | — | — | US | disclosed |
| US-7268119-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-09-11 | — | — | US | disclosed |
| US-7268119-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-09-11 | — | — | US | disclosed |
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | ADORA2A 166/4885ADA 61/4885ADK 119/4885 |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | NME1, NME2, NTPCR | ADORA2A 342/4885ADA 85/4885ADK 203/4885 |
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | ADORA2A 166/4885ADA 61/4885ADK 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.